- Home
- CTOR vs CRDL Comparison
CTOR vs CRDL Comparison
Compare CTOR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- CRDL
- Stock Information
- Founded
- CTOR 2021
- CRDL 2017
- Country
- CTOR United States
- CRDL Canada
- Employees
- CTOR N/A
- CRDL N/A
- Industry
- CTOR
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTOR
- CRDL Health Care
- Exchange
- CTOR NYSE
- CRDL Nasdaq
- Market Cap
- CTOR 126.2M
- CRDL 140.1M
- IPO Year
- CTOR N/A
- CRDL N/A
- Fundamental
- Price
- CTOR $1.55
- CRDL $2.20
- Analyst Decision
- CTOR Strong Buy
- CRDL Strong Buy
- Analyst Count
- CTOR 1
- CRDL 3
- Target Price
- CTOR $6.00
- CRDL $9.00
- AVG Volume (30 Days)
- CTOR 87.9K
- CRDL 354.4K
- Earning Date
- CTOR 08-12-2024
- CRDL 11-12-2024
- Dividend Yield
- CTOR N/A
- CRDL N/A
- EPS Growth
- CTOR N/A
- CRDL N/A
- EPS
- CTOR N/A
- CRDL N/A
- Revenue
- CTOR N/A
- CRDL N/A
- Revenue This Year
- CTOR N/A
- CRDL N/A
- Revenue Next Year
- CTOR N/A
- CRDL N/A
- P/E Ratio
- CTOR N/A
- CRDL N/A
- Revenue Growth
- CTOR N/A
- CRDL N/A
- 52 Week Low
- CTOR $1.53
- CRDL $0.66
- 52 Week High
- CTOR $49.00
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- CRDL 54.56
- Support Level
- CTOR N/A
- CRDL $1.78
- Resistance Level
- CTOR N/A
- CRDL $2.63
- Average True Range (ATR)
- CTOR 0.00
- CRDL 0.17
- MACD
- CTOR 0.00
- CRDL 0.03
- Stochastic Oscillator
- CTOR 0.00
- CRDL 49.71
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.